The blueprint, a basic outline and core message the FDA thinks should be conveyed to prescribers, is open to stakeholder comment. The final blueprint will be published to the FDA website for use by providers of continuing education in creating courses for the safe prescribing of opioids.
Related Articles on Opioid:
Opioid Abuse Increasing in Older White Women
Oregon’s High Rate of Pain Drug Abuse Linked to Heavy Prescribing
Opioid Pain Reliever Overdose Kills More than Heroin and Cocaine Combined
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
